drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody
drug_description
An anti-PSMA monoclonal antibody that binds prostate-specific membrane antigen (FOLH1) on prostate cancer cells; upon binding and internalization, it enables tumor-targeted uptake of the attached radionuclide for imaging and potential cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
NY108 is a PSMA (FOLH1)-targeted monoclonal antibody linked to lutetium-177. After binding PSMA on prostate cancer cells and being internalized, it delivers tumor-targeted beta radiation that can induce cytotoxic DNA damage, while its gamma emissions enable SPECT imaging of biodistribution.
drug_name
NY108
nct_id_drug_ref
NCT05815394